FIN-524 / Finch Therap - LARVOL DELTA

Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD (GlobeNewswire) - "Finch Therapeutics Group, Inc...announced that it will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Limited ('Takeda')....FIN-524 and FIN-525 are investigational, orally administered targeted microbiome product candidates composed of bacterial strains selected for their potential immuno-modulatory properties."

Licensing / partnership • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results (GlobeNewswire) - "Finch Therapeutics Group, Inc...provided corporate updates and reported financial results for the second quarter ended June 30, 2022....Research and development (R&D) expenses were relatively flat, with $13.9 million of expenses for the second quarter of 2022, compared to $14.0 million for the same period in 2021....This increase was offset by a decrease in costs related to Finch’s inflammatory bowel disease program due to the transition of primary responsibilities for TAK-524 from Finch to Takeda in the third quarter of 2021..."

Commercial • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program (GlobeNewswire) - "Finch Therapeutics Group, Inc...announced that Takeda Pharmaceutical Company Limited...has elected to accelerate the transition of development responsibility for the FIN-524 ulcerative colitis development program. Takeda will assume primary development responsibility for the program, now known as TAK-524, ahead of the planned initiation of clinical-stage development. The transition will enable Takeda to leverage its expertise in inflammatory bowel disease (IBD) throughout the clinical development of FIN-524/TAK-524."

Licensing / partnership • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis